Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Recruiting · NCT07166003 · Observational (researchers observe without assigning treatment) · Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
View the official record on ClinicalTrials.gov →Interventions studied
Anti-Tumor DrugsPneumonectomylobectomyradiotherapy
What this trial is about
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Who can take part
Age range
18 Years to 79 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Aged between 18 and 79 years;
- Received at least two cycles of neoadjuvant immunotherapy;
- ECOG performance status score of 0;
- Complete clinical information including imaging data available.
Exclusion criteria
- Diagnosed with or suspected active autoimmune diseases;
- Presence of EGFR/ALK sensitive mutations;
- Pregnant or breastfeeding women;
- Previous anti-tumor therapies including chemotherapy or radiotherapy;
- History of organ transplantation or hematopoietic stem cell transplantation;
- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
- Uncontrolled diabetes mellitus;
- Uncontrolled hypertension.
Where it is running
1 location listed.
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing, China